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Intratumoral regulatory T (Treg) cells are
important in lung cancer, but it has been
difficult to dissect their mechanisms of
action. Jacks and colleagues
demonstrate that intratumoral Treg cells
function within tumor-associated tertiary
lymphoid structures to suppress anti-
tumor T cell responses in a mouse model
of lung cancer.
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Infiltration of regulatory T (Treg) cells into many tu-
mor types correlates with poor patient prognoses.
However, mechanisms of intratumoral Treg cell func-
tion remain to be elucidated. We investigated Treg
cell function in a genetically engineered mouse
model of lung adenocarcinoma and found that Treg
cells suppressed anti-tumor responses in tumor-
associated tertiary lymphoid structures (TA-TLSs).
TA-TLSs have been described in human lung can-
cers, but their function remains to be determined.
TLSs in this model were spatially associated with
>90% of tumors and facilitated interactions between
T cells and tumor-antigen-presenting dendritic cells
(DCs). Costimulatory ligand expression by DCs and
T cell proliferation rates increased in TA-TLSs upon
Treg cell depletion, leading to tumor destruction.
Thus, we propose that Treg cells in TA-TLSs can
inhibit endogenous immune responses against tu-
mors, and targeting these cells might provide thera-
peutic benefit for cancer patients.
INTRODUCTION
Non-small-cell lung cancer (NSCLC), including lung adenocarci-
noma, accounts for 25% of all cancer deaths (Jemal et al.,
2010), and despite improvements in therapy, NSCLC mortality
remains around 80% (http://seer.cancer.gov/statfacts/html/
lungb.html). Immunotherapy uses the immune system to attack
cancer and has demonstrated durable tumor regression in
‘‘immunogenic’’ tumor types such as melanoma (Pardoll,
2012). Yet, until recently, NSCLCwas considered ‘‘non-immuno-
genic’’ because tumors responded poorly to immunotherapeu-
tics (Raez et al., 2005). Furthermore, it was thought that
compared to melanomas, lung tumors might not elicit strong
endogenous T cell responses, even though these tumor types
had similar numbers of mutations and predicted neoantigensIm(Rajasagi et al., 2014; Vogelstein et al., 2013). The recent
success of immune-checkpoint inhibitors in NSCLC patients
demonstrates that anti-tumor T cell responses do exist in a sig-
nificant fraction of lung cancer patients, but they are functionally
inhibited by poorly understood immunosuppressive mecha-
nisms (Pardoll, 2012). Overcoming these mechanisms will be
essential for generating more-effective immunotherapies for
this disease.
Regulatory T cell (Treg) deficiency, through mutation or
deletion of X-linked forkhead box P3 (Foxp3), leads to a
fatal lymphoproliferative disease (Josefowicz et al., 2012).
However, Treg cells might also facilitate tumor progression
by suppressing adaptive immunity against tumors. Treg cell
depletion in transplantable, carcinogen-induced, and autoch-
thonous tumor models demonstrates increased anti-tumor im-
mune responses, even against previously established tumors,
which results in reductions in tumor size (Sakaguchi, 2004;
Bos et al., 2013; Teng et al., 2010). Yet, many questions remain
about how and where Treg cells function in the context of
developing tumors.
Treg cells suppress self-reactive T cells in secondary lymphoid
organs (SLOs; e.g., lymph nodes [LNs] and spleen). Similarly,
Treg cells can suppress anti-tumor responses in tumor-draining
LNs (Boissonnas et al., 2010; Campbell and Koch, 2011). How-
ever, Treg cells inside tumor tissues might also be important in
natural tumor progression. Treg cells are often enriched in tumor
tissue, and a high ratio of intratumoral Treg cells to effector
T cells generally predicts poor patient outcomes (Fridman
et al., 2012). Furthermore, the ability of anti-CTLA-4 antibodies
to deplete intratumoral, but not LN, Treg cells is critical for their
efficacy in animal cancer models (Marabelle et al., 2013; Selby
et al., 2013; Simpson et al., 2013). However, although previous
data have suggested that intratumoral Treg cells promote tumor
development, the mechanisms by which they do so remain to be
fully determined.
In patients, across cancer types, lymphocytes can be found in
LN-like, large, complex tumor-associated tertiary lymphoid
structures (TA-TLSs; Fridman et al., 2012; Goc et al., 2013).
Among patients with early-stage NSCLC, 70% have TA-
TLSs, which contain immune cells with an activated phenotype,
as do TLSs observed after viral infection (Neyt et al., 2012; demunity 43, 579–590, September 15, 2015 ª2015 Elsevier Inc. 579
Chaisemartin et al., 2011; Dieu-Nosjean et al., 2008). TA-TLS
presence also correlates with increased overall survival. Thus,
it is thought that TA-TLSs promote anti-tumor responses. How-
ever, TA-TLSs have not been described in animal models, and
their proposed functions have not been experimentally tested.
It is also uncertain whether immunosuppressive pathways are
active in TA-TLSs.
Genetically engineered mouse models (GEMMs) of cancer
have greatly informed the understanding of tumor biology and
therapy (Hayes et al., 2014; Kwon and Berns, 2013). Tumors in
GEMMsdevelop fromuntransformedcells in their nativemicroen-
vironment and, importantly, in the presence of a fully functional
immune system. However, tumors in GEMMs are often poorly
immunogenic, and consequentially, the use of GEMMs for tumor
immunology studies has lagged (DuPage and Jacks, 2013). We
previously programmed autochthonous sarcomas and lung ade-
nocarcinomas in ‘‘KP’’ (KrasLox-STOP-Lox(LSL)-G12DTrp53flox/flox)
mice to express ‘‘LucOS,’’ firefly luciferase fused to a portion of
ovalbumin (ova, encoding the potent T cell OT-I and OT-II anti-
gens) and the antigenic 2C peptide (DuPage et al., 2011; DuPage
et al., 2012). In both tumor types, tumor-specific T cells had a sig-
nificant impact on tumor development, but disease outcomes
differed. T cells prevented the development of LucOS-expressing
sarcomas and, consequentially, only ‘‘edited’’ (LucOS-negative)
sarcomas developed (DuPage et al., 2012). In contrast, although
T cells restrained the growth of LucOS-expressing lung tumors
early in the disease course, they could not prevent it (DuPage
et al., 2011).Moreover, this initial impact on tumor growthwas fol-
lowed by immune suppression, despite the confirmed expression
of LucOS by tumors. Therefore, whereas sarcomas escaped
immune control via editing, lung tumors escaped because the
anti-tumor response itself was suppressed. The mediators of
immunosuppression in the lung adenocarcinoma model are un-
known. Because Treg cells are prominent in early LucOS-ex-
pressing tumors (DuPage et al., 2011), we reasoned that they
might be important in immune suppression in later-stage tumors.
Here, we investigated the functions of intratumoral Treg cells in
advanced lung adenocarcinomas.
RESULTS
Treg Cells Accumulate in Tumor-Bearing Lungs and
Have an Activated Phenotype
To identify and deplete Treg cells in autochthonous lung tumors,
we bred KP mice to Foxp3IRES-DTR-GFP mice (Kim et al., 2007), in
which all CD4+FoxP3+ Treg cells express diphtheria toxin recep-
tor (DTR)-GFP fusion protein. Lung tumors in ‘‘KP-F’’ mice (F:
FoxP3DTR-GFP/DTR-GFP or KP-FoxP3DTR-GFP/y) were initiated by
intratracheal (i.t.) administration of non-replicating lentiviruses
co-expressing LucOS and Cre-recombinase (LucOS/Cre LV;
DuPage et al., 2011). In lung epithelial cells, Cre activates onco-
genic KrasG12D and deletes Trp53, resulting in the development
of autochthonous lung adenocarcinomas over a period of
months (Figure S1A; DuPage et al., 2011). After 20–24 weeks,
KP-F mice had a mixture of low- and high-grade lung adenocar-
cinomas with few infiltrating lymphocytes (Figure S1B).
To identify circulating and lung-tissue Treg cells in flow cyto-
metric analysis, we labeled the circulating cells with anti-CD45
(CD45PE-CF594) antibodies injected prior to sacrifice (Figure S1C).580 Immunity 43, 579–590, September 15, 2015 ª2015 Elsevier Inc.In control week-20 LucOS-infected P-F (Kras+/+) mice, most
‘‘lung’’ CD4+ T cells or Treg cells were in the circulation
(CD45PE-CF594+), but in tumor-bearing animals, a large fraction
of the CD4+ T cells and Treg cells were in the lung tissue
(CD45PE-CF594; Figure 1A). This corresponded with a >20-fold
increase in lung-tissue Treg cell numbers, whereas circulating
Treg cell numbers remained unchanged (Figure 1B). Similar re-
sults were seen with excised tumors (data not shown).
Immunophenotyping demonstrated that 60%–80% of the
lung-tissue Treg cells in tumor-bearing mice expressed CD103
(integrin aE; Figure 1C), a Treg cell marker found in sites of
inflammation (Feuerer et al., 2010; Sather et al., 2007; Suffia
et al., 2005). Furthermore, 50% of the CD103+ Treg cells also
expressed killer cell lectin-like receptor G1 (KLRG1), which is
typically associated with terminally differentiated immune cells
(Beyersdorf et al., 2007; Cheng et al., 2012; Joshi et al., 2007;
Robbins et al., 2005). In contrast, the presence of tumors did
not affect CD103 and KLRG1 expression by Treg cells in the
lung circulation, tumor-draining mediastinal LN (mLN), or control
inguinal LNs (iLNs; Figure 1C). CD103+KLRG1+ double-positive
(DP) Treg cells expressed high amounts of several additional
molecules previously associated with activated Treg cells,
including two markers of T cell activation, CD44 and CD69,
and the ectonucleotidase CD39 (Figure 1D). DP Treg cells also
expressed high amounts of the interleukin-2 (IL-2) high-affinity
receptor IL-2Ra (CD25), as well as the immunoinhibitory recep-
tor PD-1 (Figure 1D). The expression of these markers by DP
Treg cells was higher than that of CD103+KLRG1 single-posi-
tive (SP) or CD103KLRG1 double-negative (DN) Treg cells in
the lung tissue (Figure 1D). Treg cells in lung tissue also ex-
pressed higher amounts of CTLA-4 than did Treg cells in the
mLN (Figure 1E). Together, these data suggest that similar to
Treg cells found at sites of inflammation, tumor-infiltrating Treg
cells exhibit an activated phenotype. Because few Treg cells
with this phenotype were observed in the draining LN, it is likely
that Treg cells acquired their activated phenotype within the
tumor-bearing lung.
Treg Cells Actively Suppress Anti-tumor Responses
Targeting Established Lung Adenocarcinomas
We next assessed the effect of Treg cell depletion on tumors in
KP-Fmice. Two intraperitoneal (i.p.) injections of diphtheria toxin
(DT, 50 mg/g) into tumor-bearing (18–20 weeks after infection)
or non-tumor-bearing KP-F mice efficiently eliminated Treg cells
in the lungs and lymphoid tissues (Figures 2A, S2A, and S2B).
However, FoxP3DTR mice, but not FoxP3WT mice, became
moribund within 2–3 weeks of depletion and required sacrifice
(Figure S2C). Additionally, in tumor-bearing KP-Foxp3DTRGFP/+
(KP-F/+) mice, in which only 50% of all Treg cells express
DTR-GFP as a result of X inactivation (Figure S2D), DT treatment
did not cause morbidity (data not shown). Therefore, the
observed morbidity was caused by an autoimmune response
triggered by transient Treg cell depletion and was not a side
effect of DT treatment. Consistent with this, 12 days after deple-
tion, in KP-F mice, but not in KP-F/+ mice, most T cells were
activated (CD44hi), there was dramatic lymphadenopathy and
splenomegaly, and lymphocytes had infiltrated several tissues
throughout the body (Figures S2E–S2H; Kim et al., 2007). Of
note, regardless of tumor status, in Treg-cell-depleted mice we
Figure 1. Treg Cells in Tumor-Bearing
Lungs Have an Activated Phenotype
KP-F and P-F (control) mice were analyzed
20 weeks (18–24 weeks) after LucOS/Cre LV
infection by flow cytometry.
(A) FACS plots gated on lung CD4+ T cells. Tissue
(black) and circulating (red) FoxP3+ Treg cell
frequency is indicated. Note that control and
uninfected (naive) lungs were indistinguishable.
n > 30 mice.
(B) Graph of total CD4+ T cells and tissue and
circulating Treg cell numbers in lungs from naive
(n = 11) and tumor-bearing (week 20, n = 30)
animals. Median and relative differences are
indicated. *p = 0.03.
(C) CD103 and KLRG1 on the Treg cell populations
in (A). n > 30 mice.
(D) Expression of indicated markers by circulating
DN (filled gray line) and tissue DN, SP, and DP Treg
cells (red, dashed blue, and black lines, respec-
tively). Histograms are gated as shown in (C).
n = 9–35 mice.
(E) CTLA-4 expression by mLN (gray filled line),
mesenteric (mes) LN (dashed blue line), and lung-
tissue Treg cells (black line). n = 7 mice.observed lymphocytic infiltration near the major airways in the
lungs and goblet cell metaplasia, similar to what is seen in
FoxP3-deficient mice (Figures S2I and S2J; Lin et al., 2005).
However, in non-tumor-bearing animals, the alveolar spaces in
the lungs (where tumors normally develop) were free from
infiltration.
To track tumor cell fate after Treg cell depletion, we bred KP-F
mice to Rosa26LSL-tdTomato(tdT) mice to generate ‘‘KPT-F’’ mice,
in which Cre induces tdT expression in tumor cells (Figure S1A;
Madisen et al., 2010). Immunofluorescence (IF) staining of tu-
mors from untreated week-20 KPT-F mice demonstrated that
they were composed of abundant, healthy-appearing tdT+ tumor
cells that were arranged primarily in papillary structures with
EpCAM staining junctions between adjacent tumor cells (Fig-
ure 2B). In contrast, day-12 Treg-cell-depleted tumors had aImmunity 43, 579–590, Serange of cellular infiltration and disruption
of regular tissue architecture (Figure 2B).
Quantification of 85 control and 108
Treg-cell-depleted tumors showed that
>80% of the Treg-cell-depleted tumors
had moderate or severe disruption (Fig-
ure 2C). To visualize tumor destruction
more comprehensively, we performed
CLARITY (Chung et al., 2013) on lungs
from control and Treg-cell-depleted
KPT-F mice. This allowed whole-tumor
3D confocal imaging of 15 control and
10 Treg-cell-depleted tumors. Tumors
from the Treg-cell-depleted mice showed
extensive cellular infiltration (Figure 2D
and Movie S1) and contained cavities
filled with densely packed (non-tumor)
cells. Furthermore, tumor cells in the
Treg-cell-depleted mice were thin andelongated and no longer formed connections with adjacent tu-
mor cells (Figures 2B and 2D). These data demonstrate that
the cellular density andmorphology of tumors were severely dis-
rupted by Treg cell depletion.
Immunohistochemical (IHC) analysis showed that most of the
infiltrating cells in Treg-cell-depleted tumors were CD45+ im-
mune cells (Figure 2E). Infiltration was highly focused in the areas
near tumors, given that distal areas were free of immune infil-
trates (Figure S3A). Immune infiltration was not observed in tu-
mors from Treg-cell-depleted KPT-F/+ mice, indicating that
depletion of more than half of the Treg cell population was
required for anti-tumor effects (Figure S3B). Fluorescence-acti-
vated cell sorting (FACS) analysis revealed that the number of
CD4+ andCD8+ T cells in the lung increased after Treg cell deple-
tion (Figure 2F). In contrast, the number of B cells did notptember 15, 2015 ª2015 Elsevier Inc. 581
Figure 2. Treg Cells Maintain Immune Quiescence in Advanced Tumors
Week-18 to week-20 LucOS/Cre-LV-infected KP-F (A) or KPT-F (B–H) mice were treated 13 (A) or 23 (B–H) with i.p. DT (50 ng/g) and analyzed 2 (A) or 12 (B–H)
days later.
(legend continued on next page)
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increase. IF analyses showed that in undepleted mice, CD3+
T cells in tumors were primarily located within or near blood ves-
sels, and CD11c+ macrophages were located within airway-like
pockets surrounded by tumor cells (Figures S4A and S4B). In
contrast, in the absence of Treg cells, CD4+ and CD8+ T cells
were located throughout the tumor parenchyma (Figure 2G),
and tumors were heavily infiltrated by macrophages that were
faintly positive for tdT (Figure 2H). Moreover, a small number of
macrophages had tdT+ vesicles, suggesting phagocytosis of
tumor cells. Together, these data demonstrate that Treg cells
actively suppress immune destruction of established tumors.
Lung-Tissue Treg Cells Are Contained within TA-TLSs
We next investigated Treg cell localization in tumor-bearing
lungs. Tumors in week-20 KP-F mice had few infiltrating Treg
cells, and instead, most Treg cells (>80-fold increase) were
located in perivascular immune cell patches resembling TLSs
(Figures 3A and 3B). These structures also contained CD11c+
dendritic cells (DCs) and B220+ B cells, two cell types that
have the potential to interact directly with Treg cells (Figure 3C).
TA-TLSs have been observed in patients with lung adenocarci-
noma (Fridman et al., 2012), but not in animal tumor models.
Therefore, we quantified the extent to which TLSs were associ-
ated with tumors in this model and identified whether they dis-
played features of TA-TLSs in human cancers.
Because tumors span several hundred microns, we reasoned
that analyses of thin (5-mm) lung sections might underestimate
the presence of TLSs in tumor-bearing lungs. Therefore, we
quantified the presence of TLSs in 30-mm-thick sections of tu-
mor-bearing lungs from eight mice and counted the number of
tumors that were associated with TLSs in three in-silico-recon-
structed tumor-bearing lung lobes (Figure 3D). Analysis of the
30-mm sections revealed that 60% (18/31) of tumors were
directly associated with at least one TLS (defined as B cell clus-
ters of >10 cells directly associated with T cells), and analysis of
the in-silico-reconstructed lungs showed at least one TLS asso-
ciated with 93% (70/75) of tumors analyzed (data not shown).
We next used IF to characterize the cellular and structural
components of TLSs in thick sections of tumor-bearing lungs.
TLSs varied greatly in size and complexity, although this might
be due to the fact that individual sections only capture part of
a given TLS. TA-TLSs in human cancers can have B and T cell
zones organized by follicular dendritic cells (FDCs) and fibro-
blastic reticular cells (FRCs). Similarly, in this model, mature(A) FACS plots show lung CD4+ T cells and are gated as in Figure 1A. n > 6 mice
(B) Confocal IF images show the range (no or low, moderate, or severe) of tumor
mice. Red, tdTomato+; green, EpCAM; blue, DAPI; dashed line, tumor border.
(C) Quantitation of tumor destruction from images in (C). n = 85 and 13 control tumo
respectively.
(D) Control (left panels) and Treg-cell-depleted (right panels) lungs were optica
tdTomato+; green, YO-PRO-1. n = 15 and 7 control tumors and mice, respectiv
Movie S1.
(E) IHC images show control and Treg-cell-depleted tumors for lung (NKX2.1, br
respectively, and 55 and 9 Treg-cell-depleted tumors and mice, respectively.
(F) Graph of median lung-tissue CD4+ and CD8+ (Thy1.2+) T cell and (B220+ CD19+
(white bars, n = 5) ± SEM. *p = 0.0150, **p = 0.0175.
(G) Confocal IF images show control (n = 39) and Treg-cell-depleted (n = 15) tum
(H) Confocal IF image shows a Treg-cell-depleted tumor. Red, tdTomato+; green
macrophage with tdT+ vesicles (the z depth is different than in the larger image).
ImTLSs had clearly defined B220+ B cell and CD3+ T cell areas,
which were distinct from the NKX2.1+ tumor areas (Figures 3E–
3I). Moreover, TLSs all contained Treg cells, whichwere primarily
located in the T cell areas (Figure 3E-II). About 30%of the time, B
cell areas in the TLSs contained detectable CR1+ cells with long
processes that were morphologically similar to FDCs (Fig-
ure 3E-III). These cells also expressed the B cell chemoattractant
CXCL13 and made direct contact with B cells (Figure 3E-III and
Movie S2A). We also observed that many T cells in the T cell
areas were in direct contact with ERTR-7+CCL21+ FRC-like cells
(Figure 3E-IV and Movie S2B). The presence of FRC- and FDC-
like cells in TA-TLSs suggests that they could help to organize
and support infiltrating B and T cells.
Human TA-TLSs contain high endothelial venules (HEVs),
which in LNs constitutively recruit B and T cells from the circu-
lation (de Chaisemartin et al., 2011; Neyt et al., 2012). We
noted prominent, large CD31+PNAd+ HEV-like structures, in
many of which T cells in the lumen were associated with the
vessel wall (Figures 3E–3V and Movie S2C). This indicates
that HEV-like structures could be recruiting circulating
T cells into TA-TLSs in this model, as has been hypothesized
in humans. Together, these data demonstrate that TLSs asso-
ciated with LucOS-expressing lung adenocarcinomas have
hallmarks of LNs and phenotypically mirror TA-TLSs seen in
cancer patients.
TLSs Facilitate T Cell Entry into and Activation in the
Tumor Microenvironment
It has been speculated that TA-TLSsmight be a site for local acti-
vation of tumor-specific T cells (Goc et al., 2013), but this possi-
bility remains untested. Therefore, we focused on examining the
function of TA-TLSs in vivo. Because LucOS/Cre LV encodes the
antigenic portions of ova, we used ova-specific T cell receptor
(TCR) transgenic (Tg) OT-I CD45.1+CD8+ T cells to analyze hom-
ing to and antigen presentation in TA-TLSs (outlined in Figure 4A).
As a negative control, LCMV-specific P14 Tg CD45.1+CD8+
T cells were used because their TCR recognizes an antigen not
present in LucOS. We activated the OT-I and P14 T cells
in vitro to generate memory T cells, which are more sensitive
for the presence of antigens (Kaech and Ahmed, 2001). Next,
the OT-I and P14 T cells were labeled with the cell-proliferation
dyes cell trace violet (CT-V) and eFluor670 (CT-670), respec-
tively, mixed at a 1:1 ratio, and adoptively transferred
into week-20 tumor-bearing CD45.2+ KP-F mice or control.
destruction in untreated (left panel) and Treg-cell-depleted (right three panels)
rs andmice, respectively, and 108 and 17 Treg-cell-depleted tumors andmice,
lly cleared with CLARITY. Images show optical slices through tumors. Red,
ely, and 10 and 3 Treg-cell-depleted tumors and mice, respectively. See also
own) and immune (CD45, pink) cells. n = 71 and 11 control tumors and mice,
) B cell numbers in Treg-cell-depletedmice (black bars, n = 6) and control mice
ors. Red, tdTomato+; green, CD4; blue, CD8+ T cells.
, CD11c+ macrophage (large round cells). The inset shows an optical slice of a
n = 4 mice.
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Figure 3. Treg Cells in Tumor-Bearing
Lungs Are Located in TA-TLSs
KP-F or KPT-F mice were analyzed 18–20 weeks
after LucOS/Cre LV infection.
(A) IHC images show FoxP3 (black), hematoxylin
(blue), and eosin (pink). Tumor, dashed line; TLS,
solid line; left panel, 43; right panel, 203. n = 10
mice.
(B) Median Treg cell number in tumors (n = 88) and
TLSs (n = 45) from 9 mice. Normalized by pixel
area. *p = 3.89 3 1025.
(C) IF image shows TLSs. Red, CD11c; green,
FoxP3; blue, B220; white, DAPI. n = 6 mice.
(D) 3D rendering of an in-silico-reconstructed tu-
mor-bearing lung lobe. 20 IF sections (50 mM,
1-mm depth) were imaged by confocal micro-
scopy. Blue, NKX2.1; red, CD3; green, B220.
Center panel is the same as the left, except that
NXK2.1 was removed. Right panel, TLS in box.
n = 3 mice.
(E) Confocal IF images show a TLS in serial stained
sections (30 mm) stained for indicatedmarkers. The
tumor border (dotted line) and TLS (solid line) are
shown in (I). Images highlight (II) cyan FoxP3+ Treg
cells, (III) red CR1+ FDCs, (IV) green ER-TR7+
FRCs, and (V) green PNAd+CD31+ HEVs. n = 16
mice.non-tumor-bearing CD45.2+ P-F mice. On days 2 and 3 after
transfer, homing, proliferation, and activation status were as-
sessed by FACS and IF. When OT-I and P14 T cells were trans-
ferred to control mice, neither cell type appreciably entered the
lung tissue, consistent with a lack of TLSs in these mice (Fig-
ure 4B). In contrast, upon transfer into tumor-bearing hosts,
both OT-I and P14 T cells entered the lung tissue. This suggests
that like LNs, TLSs in this model have the capacity to recruit acti-
vated T cells from the circulation. Both P14 and OT-I T cells were
found in the lung tissue, but by IF a greater fraction of the OT-I
T cells were located in the TLS (Figure 4C and Figure S5A).
Furthermore, OT-I T cells were observed to interact with DCs
in the T cell areas of the TLSs (Figure 4D). To determine whether
these contacts were functionally relevant, we assessed whether
OT-I and P14 T cells form immunologic synapses in vivo with
DCs. Sections were stained with g-tubulin (a marker of the
microtubule-organizing center [MTOC]) and CD11c, and immu-
nologic synapses were quantified on the basis of MTOC position
and interactionwith a DC (Figure S5B). In cells forming synapses,
theMTOC is repositioned to lie behind the synapse and, as such,
can be used for determining the direction in which a T cell is ori-
ented (Billadeau et al., 2007). According to this metric, along with584 Immunity 43, 579–590, September 15, 2015 ª2015 Elsevier Inc.the accumulation of cell-proliferation
dye (which non-specifically labels cellular
protein) at the T-cell-DC interface, OT-I
T cells formed 2.7-fold more synapses
than did P14 T cells in TLSs (Figure 4E).
A similar increase was seen among OT-I
T cells transferred into LucOS/Cre-LV-in-
fected versus Cre-LV-infected recipients,
which have tumors that do not express
LucOS (data not shown). Therefore,although OT-I and P14 T cells were both recruited into tumor-
bearing lungs, OT-I T cells preferentially interacted with DCs in
TLSs. This interaction had a meaningful effect on the OT-I
T cells, such that they upregulated CD69, an early marker of
T cell activation, and proliferated within lung tissue, whereas
P14 T cells did not (Figure 4F). Similar activation and proliferation
patterns were seen in the tumor-draining mLN, but not in the
iLNs, spleen, or lung circulation (Figure 4F and data not shown).
OT-I T cells did not upregulate CD69 or proliferate in the lung
tissue or mLN when transferred into control P-F mice (data not
shown). These data clearly demonstrate that infiltrating T cells
can interact with tumor antigens in both the mLN and the
TA-TLSs.
Because some DCs in the TLSs could have been directly in-
fected by LucOS/Cre LV (20 weeks prior), and thus their presen-
tation of antigens might not be tumor specific, we analyzed DCs
in KPT-F mice for the presence of tdT by IF. Given that the highly
active and ubiquitously expressed CAG promoter drives tdT
expression after Cre-mediated recombination in KPT-F mice
(Madisen et al., 2010), direct infection of any cell type results
in strong tdT signal. 20 weeks after LucOS/Cre LV infection,
directly infected round CD11c+ macrophages were easily
Figure 4. TLSs Serve as Local Sites of
Tumor Antigen Presentation
(A) Schematic diagram for (B)–(F). In-vitro-
activated CT-670+ P14 and CT-V+ OT-I Tg
CD45.1+CD8+ T cells were transferred into
week-20 LucOS/Cre-LV-infected CD45.2+
tumor-bearing KP-F and control P-F recipients.
(B) FACS plots show lung CD45.1+CD8+ P14 and
OT-I T cells 2–3 days after transfer. n > 12 mice
per group.
(C) Graph shows the median fraction (± SEM) of
transferred OT-I (black bars, n = 620) or P14
(white bars, n = 238) CD8+ T cells in the indicated
tissue (see also Figure S5A). *p = 1.89 3 103,
**p = 3.59 3 103.
(D) Confocal IF images of a TLS. Green, CT-V
(OT-I T cells); blue, NKX2.1; red, CD3 (left panel,
n = 13) or CD11c (right panel, n > 20).
(E) Graph shows the mean fraction (± SEM) of
OT-I (black bar, n = 231) or P14 (white bar,
n = 122) T cells forming synapses (see also Fig-
ure S5B). *p = 5.62 3 1011.
(F) FACS plots show transferred P14 or OT-I CD8+
T cells (gated as in Figure 5B). n > 12 recipients.
(G) Confocal IF image shows a tumor and TLS in
week-20 LucOS/Cre-LV-infected KPT-F mice.
Green, CD3; cyan, CD11c (DCs are small cells);
red, tdTomato. Note the signal-intensity differ-
ence between tumor cells and DCs. n = 5 mice.identified on the basis of an abundant tdT signal, similar in inten-
sity to that in tumor cells (data not shown). In contrast, some
CD11c+ DCs (distinguished from macrophages on the basis of
their smaller size and dendritic morphology; Thornton et al.,
2012) had faint signal for tdT in TA-TLSs in KPT-F mice, implying
that these cells had phagocytosed tumor-derived products
(Figure 4G). Additionally, we sorted lung-tissue DCs from tu-
mor-bearing lungs and confirmed that they could present
tumor-derived antigens to naive OT-I CD8+ T cells in vitro (Fig-
ures S5C and S5D). Together, these data demonstrate that
much like the tumor-draining LNs, TA-TLSs in this tumor
model are functional structures capable of recruiting circulating
CD8+ T cells and facilitating their interactions with antigen-pre-
senting DCs.
Local Immune Responses in TA-TLSs after Treg Cell
Depletion
We next assessed the impact of Treg cell depletion on tumor-
associated TLSs. The area of the lung covered by TLSs from
week-20 LucOS/Cre-LV-infected KP-F mice expanded 7-
fold in the 12 days after Treg cell depletion (Figure 5A). However,
because it was unclear whether this increase was due to local
lymphocyte expansion or recruitment, we analyzed TA-TLSsImmunity 43, 579–590, Sefor signs of immune activity at early
time points after Treg cell depletion.
Antigen-driven lymphocyte activation is
strongly correlated with cell division;
therefore, we treated mice with the
nucleoside analog bromodeoxyuridine
(BrdU) 4 hr before sacrifice to label prolif-
eration of lymphocytes. IHC analysisshowed that the proportion of proliferating lymphocytes in
TLSswas increased at days 4 and 6 after Treg cell depletion (Fig-
ures 5B and S6A). Moreover, analysis of BrdU incorporation by
FACS and IF revealed that the increased rates of proliferation
were largely among CD4+ and CD8+ T cells in TLSs, which
increased 5- and 10-fold, respectively, after Treg cell deple-
tion (Figures 5C and 5D). Collectively, these data suggest that
TA-TLSs are local sites for T cell proliferation shortly after Treg
cell depletion, although it is possible that some T cells prolifer-
ated elsewhere andmigrated to TA-TLSs during the 4-hr window
of our assay.
Treg cells directly regulate costimulatory molecules on DCs
in SLOs (Kim et al., 2007), and we therefore reasoned that
increased expression of costimulatory molecules on DCs
immediately after Treg cell depletion could indicate sites of
Treg cell function. Expression of CD80 (B7-1) and CD86
(B7-2) was examined on lung-tissue DCs 2 days after Treg
cell depletion, when changes would most likely be due to direct
effects in TLSs. FACS analysis of day-2 and day-6 Treg-cell-
depleted mice revealed that lung-tissue DCs had higher
expression of CD80 and CD86 at day 2 after depletion (Fig-
ure 5E). These data are consistent with the possibility that, as
they do in other SLOs, Treg cells in TA-TLSs regulate DCptember 15, 2015 ª2015 Elsevier Inc. 585
Figure 5. TLSs Are Sites of Immune Activa-
tion after Treg Cell Depletion
week-20 LucOS/Cre-LV-infected KP-F mice
received i.p. (A–F) or i.t. (F) DT injection. Mice
were treated with BrdU for labeling proliferating
cells (B–D).
(A) Graph quantifies TLS area (normalized to lung
area) in 22 control and 10 day-12 Treg-cell-
depleted mice. *p = 1.8 3 104.
(B) Graph shows the percent of BrdU+ lympho-
cytes in TLSs after Treg cell depletion. Day 0
indicates no DT. Points are the average of lym-
phocytes in all the TLSs in a section. Bars indicate
the median. n = 7 (days 0 and 4) and 11 (days 2
and 6). *p < 0.005. See also Figure S6A.
(C) FACS plots show BrdU staining in lung-tissue
CD8+ and CD4+ (FoxP3) T cells and B220+CD19+
B cells. Data represent the average ± SEM of three
control and six Treg-cell-depleted mice.
(D) Confocal IF images show control (n = 18 TLSs
and 9 mice) and day-6 Treg-cell-depleted (n = 57
TSLs and 12 mice) TLSs. Green, CD8; red, CD4;
white, BrdU; arrowheads, BrdU+CD8+ (green) and
CD4+ (red) T cells.
(E) Graphs show median (± SEM) CD80 and CD86
median fluorescence intensity on lung-tissue
CD11b+CD11c+MHCII+ DCs. n = 8 (no DT), 12
(day 2), 13 (day 6). Relative change is indicated. ns,
non-significant; *p < 0.05.
(F) Graph shows blind quantification of IHC on lung
sections from control mice (n = 630 tumors and
23 mice), day-12 i.p.-DT-treated mice (systemic
depletion, n = 136 tumors and 15 mice), and day-
12 i.t.-DT-treated mice (lung-restricted depletion,
n = 266 tumors and 11 mice) stained for CD45 and
NKX2.1. No or low, <30% CD45+ cell infiltration;
moderate, 30%–50%; severe, >50%. *p < 0.005.function by reducing costimulatory levels. Furthermore, after
Treg cell depletion, the overall microenvironment in the TA-
TLSs might become more immunostimulatory to promote
anti-tumor responses by T cells.
Local Treg Cell Depletion Triggers Anti-tumor
Responses Targeting Established Lung
Adenocarcinomas
Treating tumor-bearing KP-Fmice with i.p. DT causes acute sys-
temic Treg cell depletion throughout the mice. To verify that Treg
cells in the local microenvironment of the lung suppress anti-
tumor responses, we treated mice with repeated low doses of
i.t. DT to deplete Treg cells locally within the lung. Week-20
LucOS/Cre-LV-infected KP-F mice were treated with six daily
i.t. doses of 50 ng DT. Administering i.t. DT did not result in LN
enlargement, with the exception of the lung-draining mLN, and
no morbidity was observed (data not shown). Local Treg cell
depletion triggered immune infiltration of 80% of lung tumors
(Figures 5F and S6B). Therefore, local Treg cell depletion was
sufficient to trigger strong anti-tumor effects, consistent with
the idea that Treg cells in the TLSs (and possibly in the mLNs)
regulate local anti-tumor responses. Moreover, these data
demonstrate that efficient, local Treg cell depletion could be an
effective means of triggering endogenous anti-tumor immune re-586 Immunity 43, 579–590, September 15, 2015 ª2015 Elsevier Inc.sponses without the systemic toxicity associated with whole-
body Treg cell depletion.
Programmed Antigen Expression Is Not Required for
Anti-tumor Responses after Treg Cell Depletion
We next examined whether Treg cell depletion enhanced re-
sponses by the CD8+ T cells targeting the potent T cell antigens
in LucOS. Surprisingly, however, we found that the number of
endogenous SIINFEKL-specific CD8+ T cells (identified with
SIINFEKL-loaded H2-Kb MHC I tetramers) was not dramatically
altered by Treg cell depletion (Figures 6A). Additionally, the
responses of naive T cell OT-I CD8+ T cells transferred into
tumor-bearing recipients were not enhanced by the absence of
Treg cells (data not shown). These data suggest that pro-
grammed antigen expression by tumors is not required to elicit
anti-tumor responses after Treg cell depletion. Thus, we infected
KP-F and KP3 FoxP3IRES-RFP (KP-RFP) mice with Cre LV (previ-
ously referred to as Lenti-X in DuPage et al., 2011), and
18 weeks later, we treated them with DT. After 12 days, we
analyzed lung tumors for infiltration by immune cells and evi-
dence of tumor destruction. Treg cell depletion resulted in dra-
matic infiltration of lung tissues by CD45+ cells, particularly in
the perivascular and peribronchiolar regions (data not shown).
Moreover, 75% of tumors in Treg-cell-depleted mice (n = 174
Figure 6. Overt Antigen Expression by Tu-
mors Is Not Required for Anti-tumor
Response after Treg Cell Depletion
(A) FACS plots and graph show endogenous
ova-specific CD8+ T cells (identified with H2-Kb-
SIINFEKL tetramer) in control (n = 9) and day-12
Treg-cell-depleted (i.p.; n = 14) week-20 LucOS/
Cre-LV-infected KP-F mice. Plots are gated on
CD8+ T cells. Median frequency of total ± SEM is
indicated on plots. Note that no tetramer staining
was observed in Cre-LV-infected mice. ns, non-
significant.
(B) IHC images show NKX2.1 (brown) and CD45
(pink) in week-18 Cre-LV-infected KP-F (n = 15)
and KP-RFP (control, n = 6) mice 12 days after i.p.
DT injection. No or low, <30% CD45+ cell infiltra-
tion; moderate, 30%–50%; severe, >50%. n = tu-
mor number.
(C) Graph quantifies IHC in (B). Control includes
tumors from DT-treated KP-RFP mice (n = 45 tu-
mors and 6 mice) and untreated KP-F mice (n = 58
tumors and 5 mice). n = 174 Treg-cell-depleted
tumors from 10 mice.tumors from 10 mice) were moderately (immune infiltration in
30%–50% of the tumor area) or severely (greater than 50%) infil-
trated, and most showed evidence of immune-mediated tumor
disruption (Figures 6B and 6C). In contrast, 20% of the tumors
from DT-treated KP-RFP mice (n = 45 tumors from 6 mice) had
moderate or severe immune infiltration (Figures 6B and 6C).
Similarly, only 10% of non-DT-treated week-20 KP-F mice
(n = 58 tumors from 5 mice) had severe or moderate infiltration.
These data clearly demonstrate that the anti-tumor response
seen after Treg cell depletion does not require the programmed
expression of strong tumor antigens by tumors.
DISCUSSION
It is thought that the intratumoral Treg cells in cancer patients
have important roles in immunosuppression, but it has not been
possible to functionally explore these roles in humans. Here, we
have demonstrated that Treg cells regulate anti-tumor immuneImmunity 43, 579–590, Seresponses in TA-TLSs in a mouse model
of lung adenocarcinoma. We observed
that TLSs recruit T cells from the circula-
tion and facilitate their interaction with tu-
mor-antigen-presenting DCs. Treg cells in
TLSs actively suppress potent anti-tumor
responses, and thus TLSs are a primary
site for T cell expansion upon Treg cell
depletion. Subsequently, T cells andmac-
rophages infiltrate tumors, resulting in sig-
nificant tumor destruction. Collectively,
these data point to immunosuppressive
Treg cell function within TLSs as one
mechanism that prevents anti-tumor re-
sponses and allows continued tumor
development.
TA-TLSs have been observed in several
human cancer types (Fridman et al., 2012;Goc et al., 2013), but it is not known how they form or function. In
this model, TA-TLSs formed during the course of tumor develop-
ment and were closely associated with 90% of the LucOS-ex-
pressing tumors. Interestingly, antigen expression by tumors
might affect TLS formation given that TLSs in lungs from Cre-
LV-infected mice appeared larger and were located centrally in
the lungs, distal to tumors (N.S.J. and T.J., unpublished data).
In most studies, the presence of TA-TLSs correlates with bet-
ter survival for cancer patients, suggesting that TA-TLSs have
anti-tumor functions. However, one study found that high
numbers of Treg cells in TA-TLSs, but not the tumor paren-
chyma, correlated with poor survival of breast cancer patients
(Gobert et al., 2009). It has been difficult to study the function
of TA-TLSs, including how immunosuppressive pathways, like
Treg cells, influence anti-tumor responses from within these
structures. In thismodel, we observed that Treg cells were prom-
inent in TA-TLSs and that, upon Treg cell depletion, T cells within
TA-TLSs proliferated, coincident with tumor infiltration. Thus, weptember 15, 2015 ª2015 Elsevier Inc. 587
propose that TA-TLSs might serve both pro- and anti-tumor
functions depending on the state of disease progression, as
well as the presence of immunosuppressive cell types, including
Treg cells. However, TA-TLSs also probably facilitate influx of
new effector T cells into the tumor site after Treg cell depletion
through HEVs and amplify the anti-tumor response. Therefore,
TA-TLSs could be intimately involved in many aspects of the
anti-tumor immune response, both at steady state and after
therapeutic interventions.
The data presented here do not exclude the possibility that
Treg cells in this model also suppress anti-tumor responses in
the tumor-draining mLN. In contrast, because tumor antigens
are presented in TA-TLSs and the mLN, regulation of anti-tumor
immune responses most likely requires immunosuppression at
both sites. Because Treg cells function through a variety of
mechanisms (Josefowicz et al., 2012), Treg cells in TA-TLSs
and LNs could rely on distinct effector pathways. Consistent
with this idea, Treg cells in TA-TLSs were phenotypically more
activated and expressed higher levels of multiple effector
molecules. For example, Treg cells in our model (and others) ex-
pressed higher amounts of CTLA-4 in the tumor microenviron-
ment than did tumor-draining LNs (Marabelle et al., 2013;
McDermott et al., 2014; Selby et al., 2013; Simpson et al.,
2013). In the steady state, Treg cells use CTLA-4 to reduce
the amounts of costimulatory proteins on DCs, thus inhibiting
T cell activation and preventing autoimmunity (Qureshi et al.,
2011; Wing et al., 2008). Likewise, Treg cells in TLSs could
use CTLA-4 to regulate anti-tumor responses through DCs.
TA-TLS Treg cells also express high amounts of CD39, which,
along with CD73, produces adenosine, a potent T cell inhibitor
(Antonioli et al., 2013). Interestingly, chemical inhibition of
CD39 has been shown to reduce early tumor growth in a
Kras-driven Atg5-deficient mouse lung cancer model, possibly
through Treg cell function (Rao et al., 2014). Further investiga-
tion will be required to more firmly establish the functional
importance of these and other effector pathways active in
Treg cells in TLSs and to determine whether these pathways
can be therapeutically exploited for improving anti-tumor im-
mune responses.
CD8+ T cell responses against the strong ova-antigen in
LucOS were not dramatically enhanced by Treg cell depletion.
This is perhaps because Treg cells preferentially suppress re-
sponses by T cells that have weak, lower-affinity interactions
with their cognate antigen (Pace et al., 2012), more like those
seenwith self- or tumor-antigens (Aleksic et al., 2012). Therefore,
in addition to responding to Cre-derived antigens, after Treg cell
depletion, T cells could also have been responding to self-anti-
gens expressed by tumors in this model. Overexpressed and
abnormally expressed (non-mutated) antigens are frequent tar-
gets in human cancer (Finn, 2008), and advanced lung tumors
in KP mice can express embryonic proteins and proteins nor-
mally found in other locations, such as the gut (Snyder et al.,
2013). Responses against these antigens would be suppressed
under steady-state conditions, but it is possible that Treg cell
depletion permits responses by T cells with low affinity for these
tumor-associated antigens. Identification of the types of tumor
antigens recognized by T cells after Treg cell depletion will be
helpful for guiding the development of future immune-based
therapies.588 Immunity 43, 579–590, September 15, 2015 ª2015 Elsevier Inc.Immune-checkpoint blockers have enormous potential for
treating a variety of types of human cancers, but positive clinical
responses correlate with immune-related adverse events
(Pardoll, 2012). Because immune-checkpoint pathways are
important for preventing naturally occurring autoimmune dis-
eases, immunotherapies walk a fine line between promoting
strong anti-cancer effects and minimizing autoimmune toxicity.
Treg cells are prime immunotherapeutic targets. In our model,
systemic Treg cell depletion unleashed a powerful anti-tumor
response but also resulted in significant morbidity. Therefore, it
seems possible that it could be difficult to control the autoim-
mune response triggered by systemic Treg cell depletion in pa-
tients once it is initiated. This concern underscores the need to
identify mechanisms for localized therapeutic depletion or tar-
geted blockade of Treg cells in the tumor microenvironment.
For example, some CTLA-4 antibodies can deplete intratumoral
Treg cells, and treatment of metastatic melanoma patients with a
Treg-cell-depleting antibody, ipilimumab, provides an increase
in overall survival, whereas treatment with a non-depleting anti-
body, tremelimumab, does not (Hodi et al., 2010; Ribas et al.,
2013; Marabelle et al., 2013; McDermott et al., 2014; Selby
et al., 2013; Simpson et al., 2013). From a therapeutic stand-
point, specifically targeting immunosuppressive mediators
in TA-TLSs (like Treg cells) could make it possible to promote
local anti-tumor responses and maintain immune homeostasis
outside of the tumor microenvironment. Our study supports the
development of additional targets for local Treg cell inhibition
within the tumor microenvironment as a strategy that could pro-
vide safer, more-effective therapy for patients with cancer.
EXPERIMENTAL PROCEDURES
Mice and Treatments
KP and Foxp3IRES-DTR-GFP mice have been previously described (DuPage
et al., 2011; Kim et al., 2007). OT-I TCR Tg and Rosa26LSL-tdT mice (B6.Cg-
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J) were purchased from the Jackson Lab-
oratory, and P14 TCR Tg mice were purchased from Taconic. For systemic
Treg cell depletion, mice received i.p. injection of 50 ng/g DT in PBS on
days 0 and 1 (two doses). For lung-specific Treg cell depletion, mice received
i.t. injection of 50 ng DT in 50–100 ml PBS on days 0–5 (six doses). Mice toler-
ated i.t. DT well, and no morbidity or mortality was observed. Furthermore, i.t.
DT did not trigger splenomegaly or lymphadenopathy, except in the lung-
draining mediastinal LNs (data not shown). Details of BrdU labeling, in vivo la-
beling, and MRI are provided in the Supplemental Experimental Procedures.
All studies were performed under an animal protocol approved by the Massa-
chusetts Institute of Technology (MIT) Committee on Animal Care. Mice were
assessed for morbidity according to guidelines set by the MIT Division of
Comparative Medicine and were always humanely sacrificed prior to natural
expiration.
Lentiviral Production
Mice received i.t. injection of 2.53 104 to 53 104 PFU of Cre or LucOS/Cre LV
for tumor initiation. Details of the viruses and production are provided in the
Supplemental Experimental Procedures.
Tissue Isolation, Immunohistochemistry, and Immunofluorescence
Lungs were isolated, flushed with bronchoalveolar lavage and/or lung circula-
tory perfusion, and then allocated for IHC, IF, FACS, and/or CLARITY. For IHC
and IF, tissues were preserved overnight with paraformaldehyde-lysine-peri-
odate fixative, embedded in paraffin (IHC) or cryoprotected with 30% sucrose
in PBS (IF), and embedded in optimum cutting temperature compound (VWR).
Details of isolation, fixation, and IF and IHC staining are provided in the Sup-
plemental Experimental Procedures.
Confocal Imaging
Images were acquired on an Olympus FV1200 Laser Scanning Confocal
Microscope or a Nikon A1R Ultra-Fast Spectral Scanning Confocal Micro-
scope with 103, 203, and 303 objectives and analyzed with ImageJ (NIH)
and Photoshop CS4 (Adobe Systems). For whole-lung reconstructions, indi-
vidual sections were manually aligned with ImageJ and Photoshop as detailed
in the Supplemental Experimental Procedures.
Flow Cytometry
Spleens and LNs were processed as described in Joshi et al. (2007). Lungs
were prepared with a gentleMACS dissociator and C tubes (Miltenyi Biotec)
as described in the Supplemental Experimental Procedures. Samples were
analyzed with an LSR II (BD) and FlowJo software (Tree Star). Cell sorting
was performed on a FACSAria III (BD).
Statistical Analyses and Quantifications
p values from unpaired two-tailed Student’s t tests were used for all statistical
comparisons. Tumor destruction based on the disruption of tumormorphology
and infiltration by CD45+ immune cells was scored as described in the Supple-
mental Experimental Procedures.
In Vitro T Cell Activation and Adoptive Transfer
Splenocytes from OT-I or P14 TCR Tg mice were stimulated in vitro, stained
with cell-proliferation dyes, and mixed at a 1:1 ratio as detailed in the Supple-
mental Experimental Procedures. 1 3 106 to 5 3 106 cells were then trans-
ferred intravenously into week-20 LucOS/Cre-LV-infected recipient 45.2
KP-F mice.
Quantifying the Percentage of BrdU+ from IHC Sections
Sections of lungs were stained for BrdU by IHC, counterstained, and imaged
with an Aperio slide scanner (Leica). TA-TLSs (distinct clusters of lymphocytes
associated with blood vessels) were cropped with Adobe Photoshop. Crop-
ped images were quantified by CellProfiler for nuclei and BrdU+ cells for deter-
mining the fraction of proliferating lymphocytes.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, Supplemental Experimental
Procedures, and two movies and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2015.08.006.
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